True Light Capital
Overview
True Light Capital is a Greater China-focused asset manager that invests in high-quality opportunities with a nexus to or major business relationship with Greater China.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Syneron Bio | Mar 2026 | Series B | Co-investor |
| Syneron Bio | Mar 2026 | Series B | Co-investor |
| ANE (Cayman) Inc. | Feb 2026 | Buyout/LBO | Lead |
| Chengdu Zeling Biomedical Technology Co. Ltd. | Jan 2026 | Series C | Lead |
| Golden Goose | Dec 2025 | Buyout/LBO | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is True Light Capital based?
True Light Capital is headquartered in Singapore, Singapore.
When was True Light Capital founded?
True Light Capital was founded in 2021.
How many portfolio companies does True Light Capital have?
True Light Capital has 7 portfolio companies in Caplight's dataset.
What are some companies in True Light Capital's portfolio?
Recent investments visible on Caplight include Syneron Bio, Syneron Bio, ANE (Cayman) Inc., Chengdu Zeling Biomedical Technology Co. Ltd., Golden Goose.
What was True Light Capital's most recent investment?
True Light Capital's most recent investment on Caplight was in Syneron Bio in 2026.
What sectors does True Light Capital focus on?
True Light Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Consumer & Commerce, Mobility, Transportation & Logistics, Healthcare & Life Sciences, Frontier & Industrial Tech, Consumer & Commerce, AI, Data & Cloud Infrastructure, Consumer & Commerce.
What company stages does True Light Capital focus on?
True Light Capital typically invests at the Mid stage.
What is True Light Capital's AUM?
True Light Capital's assets under management are estimated between $4.0B and $4.0B.